This article considers current guidance on in-use stability testing in the European Economic Area (EEA). It highlights the problems arising from the absence of specific guidance for human medicinal products and illustrates these using two examples of different product types. Finally , a proposal is made for a guideline on in-use stability testing , specifically for human medicinal products.